Picture of Beigene logo

BGNE — Beigene Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapSucker Stock

Momentum

Relative Strength (%)
1m-10.09%
3m-28.86%
6m-54.78%
1yr-57.5%
Volume Change (%)
10d/3m+22.56%
Price vs... (%)
52w High-67.81%
50d MA-19.44%
200d MA-48.59%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-30.13%
Return on Equity-69.11%
Operating Margin-226.83%

Financial Summary

Year End 31st DecUnit201720182019202020212022E2023ECAGR / Avg
Total RevenueCNYmn/a1,310.032,9542,120.27,588.9610,025.1413,748.979.6%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%n/an/an/an/an/an/an/an/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Beigene EPS forecast chart

Profile Summary

BeiGene, Ltd. (BeiGene) is a global biotechnology company. The Company is focused on discovering, developing, manufacturing, and commercializing medicines to improve treatment outcomes and expand access for patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers, tislelizumab; an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers, and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company also has other products in its clinical stage, including BGB-283, BGB-3245, BGB-11417, BGB-A445, BGB-A425, BGB-15025, BGB-A333, BGB-A1217, and BGB-10188. The Company operates offices in 30 countries on five continents, namely the United States, China, Europe, and Australia.

Directors

Last Annual
December 31st, 2021
Last Interim
March 31st, 2022
Incorporated
October 28th, 2010
Public Since
February 3rd, 2016
No. of Shareholders
83,751
No. of Employees
8,033
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Select Market
Shares in Issue
1,450,235,805

BGNE Share Price Performance

Upcoming Events for BGNE

Similar to BGNE

Picture of 2Seventy Bio logo

2Seventy Bio

us flag iconNASDAQ Global Select Market

Picture of 4D Molecular Therapeutics logo

4D Molecular Therapeutics

us flag iconNASDAQ Global Select Market

Picture of AbCellera Biologics logo

AbCellera Biologics

us flag iconNASDAQ Global Select Market

Picture of AbSci logo

AbSci

us flag iconNASDAQ Global Select Market

Picture of ACADIA Pharmaceuticals logo

ACADIA Pharmaceuticals

us flag iconNASDAQ Global Select Market

FAQ

Or unlock with your email

Or unlock with your email